Block Inc vs Zimmer Biomet Holdings Inc — how do they compare? Block Inc trades at $80.35 (market cap $47.19B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Block Inc is far larger — about 2.7× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while Block Inc pays none. Which is the better fit depends on your goals.
| XYZ | ZBH | |
|---|---|---|
Market Cap | $47.19B | $17.36B |
Sector | Technology | Health |
52-Week High | $81.81 | $107.71 |
52-Week Low | $49.04 | $79.58 |
Enterprise Value | $42.06B | $24.40B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
XYZ trades at $80.38, up 0.55% today, with a bullish technical signal and strong analyst consensus. Recent Q1 2026 earnings beat expectations, but net income margin fell to 3.3% in 2025. The stock is supported by positive sentiment from Zacks upgrades and momentum coverage, though it faces risks from a recent $45 million settlement and mixed cash flow trends.
The outlook is cautiously optimistic, with a consensus price target of $89.64 offering ~12% upside. Key opportunities include earnings growth and Cash App strength, but risks involve credit losses, regulatory scrutiny, and a high P/E ratio of 61.95. Institutional selling and insider sales add near-term pressure.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →